NicOx S.A. today announced that blood pressure results for naproxcinod have been released.
The results were presented at an oral session of the American Society of Hypertension (ASH) Annual Scientific Meeting and Exposition in New York, by Professor William B. White, MD from the University of Connecticut School of Medicine, Farmington.
Naproxcinod is the first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug-candidate developed for the relief of the signs and symptoms of osteoarthritis. It is currently under review by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
In his presentation, Pr. White described previously undisclosed results from the pre-specified pooled analysis of the three pivotal phase 3 trials for naproxcinod (the 301, 302 and 303 studies). The abstract of the presentation has been published in a supplement of the Journal of Clinical Hypertension, the official ASH journal.
For more information, please click the link below: